prempro

Wyeth Pharmecuticals on Wednesday lost its appeal of a decision that awarded $58 million in damages to three women who claimed the company's hormone-replacement drugs caused their breast cancer. The news could bode badly for the Pfizer-owned company, which has thousands of such cases pending.

For Pfizer (PFE), most of the news lately on the legal front has been bad. But this week, Pfizer got a bit of good news regarding some of the hormone replacement therapy cases against it. A New York judge dismissed at least 23 lawsuits filed by women who claimed that the menopause drugs Prempro, Premarin and Provera had caused their breast cancers.

It seems that for Pfizer (PFE), the saga of Prempro is just beginning. Barely a month after the world's largest pharmaceutical company lost a case related to Wyeth's Prempro hormone replacement therapy drug and was ordered to pay punitive damages on top of earlier compensatory damages, it lost the...